

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

May 30, 2022

To stakeholders

Company name Renaissance Inc.
Name of Representative: Koji Naito, President & CEO
(Security Code: 4889 Tokyo Stock Exchange Growth)
Inquiries: Kazuhiro Ikeda, Director, CFO

**Notice of Transition to a Company with an Audit Committee
and Changes in Directors**

The Company resolved at a meeting of its Board of Directors held on May 30, 2022 to change from a company with a board of corporate auditors to a company with an audit and supervisory committee, subject to approval at the 23rd Ordinary General Meeting of Shareholders to be held on June 29, 2022, in order to enhance corporate governance by strengthening the supervisory function of the Board of Directors. In conjunction with this change, the Company also resolved today to nominate candidates for the Board of Directors to be proposed at the 23rd Ordinary General Meeting of Shareholders scheduled to be held on June 29, 2022, as follows

The partial amendments to the Articles of Incorporation in connection with this matter are separately disclosed in the "Notice of Partial Amendments to the Articles of Incorporation" dated today.

Particulars

1. Transition to a Company with an Audit & Supervisory Committee

(1) Purpose of the transition

- The Company intends to strengthen the supervisory function of the Board of Directors and further enhance corporate governance by strengthening the supervisory system of the Board of Directors and by making Audit & Supervisory Committee members, who are responsible for auditing the execution of duties by Directors, voting members of the Board of Directors.
- By allowing the Board of Directors to broadly delegate business execution decisions to directors, the Company aims to separate business execution and supervision, accelerate management decision-making, and further enhance corporate value.

(2) Timing of transition

At the 23rd Ordinary General Meeting of Shareholders of the Company to be held on June 29, 2022, the necessary amendments to the Articles of Incorporation will be approved and the Company will transition to a company with an Audit & Supervisory Committee.

2. Personnel Changes of Directors after Transition to a Company with an Audit & Supervisory Committee

- (1) Candidates for Directors other than Directors who are Audit & Supervisory Committee Members (to be proposed at the 23rd Ordinary General Meeting of Shareholders to be held on June 29, 2022)

Name	New Position Name	Former Job Title
Toshio Miyata	Chairman of the Board	same as on the left
Koji Naito	Representative Director, President	same as on the left

- (2) Candidates for Directors as Audit & Supervisory Committee Members (to be proposed at the 23rd Ordinary General Meeting of Shareholders of the Company to be held on June 29, 2022)

Name	New Position Name	Former Job Title
Hideyuki Ito	Outside Director, Full-time Audit & Supervisory Committee Member	Outside Corporate Auditor
Yasuo Azuma	Outside Director, Audit & Supervisory Committee Member	Outside Director
Mitsuru Ichikawa	Outside Director, Audit & Supervisory Committee Member	Outside Director
Yasunori Nishiyama	Outside Director, Audit & Supervisory Committee Member	-

Note: Mr. Hideyuki Ito, Mr. Yasuo Azuma, Mr. Mitsuru Ichikawa and Mr. Yasunori Nishiyama are candidates for Outside Director as defined in Article 2, Item 15 of the Companies Act.

- (3) Retiring Directors and Corporate Auditors (to be proposed at the 23rd Ordinary General Meeting of Shareholders to be held on June 29, 2022)

Name	Former Job Title	(Title after retirement)
Sho Kato	Director, in charge of Research & Development	Executive Officer (In charge of Medical Solutions)
Kazuhiro Ikeda	Director, CFO in charge of Administration	-
Mikio Matsukaki	Full-time Corporate Auditor	-
Hidehiro Ando	Auditor	-

End